{"filing":{"accession_number":"0001753926-26-001144","cik":"0001266806","ticker":"VANI","company_name":"Vivani Medical, Inc.","form":"8-K","filing_date":"2026-07-07","report_date":null,"primary_document":"vani-20260701.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1266806/000175392626001144/vani-20260701.htm"},"events":[{"id":16310,"run_id":14560,"accession_number":"0001753926-26-001144","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"Vivani entered into a definitive Merger Agreement on July 1, 2026, whereby its wholly owned subsidiary Cortigent will merge with ClearOne's merger subsidiary, resulting in Cortigent becoming a wholly owned subsidiary of ClearOne. Vivani shareholders will receive 12,500,000 shares of ClearOne common stock as consideration, subject to financing conditions requiring a $10–15 million capital raise for closing.","company_name":"Vivani Medical, Inc.","ticker":"VANI","filing_date":"2026-07-07","form":"8-K","submitted_at":null,"items":[{"id":14374,"accession_number":"0001753926-26-001144","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Vivani entered into a definitive Merger Agreement on July 1, 2026, whereby its wholly owned subsidiary Cortigent will merge with ClearOne's merger subsidiary, resulting in Cortigent becoming a wholly owned subsidiary of ClearOne. Vivani shareholders will receive 12,500,000 shares of ClearOne common stock as consideration. This is a material acquisition/change of control transaction disclosed under Item 1.01, with significant governance implications (board reconstitution) and financing conditions ($10–15 million capital raise required for closing).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:10:41.400930+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":16311,"run_id":14560,"accession_number":"0001753926-26-001144","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Vivani announced entry into an agreement with Novo Nordisk to evaluate NPM-139, a semaglutide implant candidate, leveraging Vivani's NanoPortal platform technology. This material strategic partnership with a major pharmaceutical company represents significant validation of the company's technology platform and development program.","company_name":"Vivani Medical, Inc.","ticker":"VANI","filing_date":"2026-07-07","form":"8-K","submitted_at":null,"items":[{"id":14375,"accession_number":"0001753926-26-001144","item_number":"8.01","item_title":"Other Information","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vivani announced entry into an agreement with Novo Nordisk to evaluate NPM-139, a semaglutide implant candidate. This is a material strategic partnership or collaboration agreement involving a major pharmaceutical company's evaluation of the company's lead product candidate. While not a traditional M\u0026A transaction, the agreement represents a significant operational and strategic development that would affect investor assessment of the company's technology validation and market opportunity. The disclosure emphasizes Novo Nordisk's interest in evaluating Vivani's NanoPortal platform technology, which reinforces confidence in the company's development program.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:10:41.400930+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14374,"accession_number":"0001753926-26-001144","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Vivani entered into a definitive Merger Agreement on July 1, 2026, whereby its wholly owned subsidiary Cortigent will merge with ClearOne's merger subsidiary, resulting in Cortigent becoming a wholly owned subsidiary of ClearOne. Vivani shareholders will receive 12,500,000 shares of ClearOne common stock as consideration. This is a material acquisition/change of control transaction disclosed under Item 1.01, with significant governance implications (board reconstitution) and financing conditions ($10–15 million capital raise required for closing).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:10:41.400930+00:00","company_name":"Vivani Medical, Inc.","ticker":"VANI","filing_date":"2026-07-07"},{"id":14375,"accession_number":"0001753926-26-001144","item_number":"8.01","item_title":"Other Information","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vivani announced entry into an agreement with Novo Nordisk to evaluate NPM-139, a semaglutide implant candidate. This is a material strategic partnership or collaboration agreement involving a major pharmaceutical company's evaluation of the company's lead product candidate. While not a traditional M\u0026A transaction, the agreement represents a significant operational and strategic development that would affect investor assessment of the company's technology validation and market opportunity. The disclosure emphasizes Novo Nordisk's interest in evaluating Vivani's NanoPortal platform technology, which reinforces confidence in the company's development program.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:10:41.400930+00:00","company_name":"Vivani Medical, Inc.","ticker":"VANI","filing_date":"2026-07-07"}]}